ILLUMINA, INC.

Illumina fired four detectors. Benford's law analysis found the leading digits of 783 award amounts deviate significantly from expected frequency, with digit 1 appearing 35 percent of the time versus the expected 30 percent, and digit 2 appearing 26 percent versus 18 percent expected. Modification growth on contract 75F40123D00001 expanded at a ratio of 254 times, far exceeding the 11-fold average for peers in NAICS 325413. The isolation forest algorithm flagged the entity as a multivariate outlier based on its combination of high award volume, extreme concentration in two agencies, and very low competition ratio. Sole-source awards comprise 88 percent of Illumina's portfolio, substantially above the 46 percent median for its 81 NAICS peers.

The Benford test yielded a Kolmogorov-Smirnov statistic of 0.137 with p-value 3.2e-13 across 783 transactions. The modification growth z-score reached 7.67 sigmas. The isolation forest raw anomaly score was -0.75 with 5 percent contamination assumption. Sole-source concentration z-score was 1.78 sigmas, with 692 of 783 awards sole-sourced.

These statistical anomalies warrant scrutiny but do not prove fraud. Illumina's scale—78 million lifetime obligations across 801 awards—and its role as a major equipment supplier to HHS may explain concentrated agency relationships and high modification frequency in long-term contracts. The Benford deviation could reflect genuine business patterns in pricing rather than manipulation. The peer group for sole-source comparison includes only 81 entities, limiting statistical power. Industry context and contract-level documentation would clarify whether these patterns reflect legitimate procurement practices.